In another clinical trial, 18 patients with metastatic castration-resistant prostate cancer were treated with Sipuleucel-T [a DC-based cancer vaccine targeting prostatic acid phosphatase (PAP)] alone or combined with intradermal co-administration of a DNA vaccine encoding PAP and GM-CSF. The gene discussed is CSF2; the disease is cancer.